“Insulin resistance in the brain” is the common factor between Alzheimer’s and the epilepsy

Researchers from the Brazilian University of São Paulo have found an exciting discovery highlighting the complex relationship between Alzheimer’s and epilepsy.

The results of the recent study, through an animal model, have proven that insulin resistance in the brain may be the common factor between these two nervous disease.

Experiments on animal models showed that the imbalance of the insulin course leads to a series of pathological changes that affect both cognitive functions and the electrical activity of the brain. When the researchers injected mice with sroptoosotosin – which causes insulin resistance – they noticed symptoms similar to Alzheimer’s and epilepsy, as animals suffered a weak memory with an increase in spastic seizures.

These results provide a scientific explanation for the observed clinical connection between the two diseases, as statistics indicate that epilepsy patients are more likely to develop Alzheimer’s with age, and epilepsy episodes are common in Alzheimer’s patients.

The researchers believe that this relationship is due to the fact that insulin resistance in the brain leads to a series of pathological changes that include:

Chronic neuritis that harms brain cells.

Disorder in the balance of neurotransmitters.

– The accumulation of harmful proteins such as, amyloid beta and the transverse protein.

– Nerve cells are damaged in the Al -Husayn area responsible for memory.

Interestingly, the study showed that this bilateral relationship, just as insulin resistance causes alzheimer’s -like changes and epilepsy, the genetically modified mice of epilepsy study also showed distinctive molecular changes for Alzheimer’s disease.

These results open new horizons in understanding neurological diseases, indicating that future treatments should take into account this complex pathological overlap. The research team is currently working to expand the scope of the study to include an analysis of human samples from treatment with treatment of treatment, in cooperation with researchers from Harvard University to study genetic and protein changes associated with these cases.

The researchers believe that the results of this study may pave the way for the development of more effective treatments targeting the radical mechanisms common to the two diseases, rather than focusing on treating symptoms only.